Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Korea Stem Cell Bank (KSCB) is a South Korean biotechnology company specializing in the extraction, cultivation, and cryopreservation of autologous stem cells. Founded in 2005 by Dr. Kim Sang-jae, the company is a pioneer in the "bio-insurance" industry, providing services for the long-term storage of an individual's own adipose-derived stem cells for future medical use. KSCB employs advanced cell expansion technologies, including the licensed cellXpansion system, to produce high-quality stem cell products for regenerative medicine and anti-aging applications. The company operates GMP-compliant facilities and has established partnerships to integrate stem cell banking with personalized healthcare. Although previously affiliated with the GemVax & KAEL group, KSCB continues to function as a dedicated provider of cell banking and research services. Its business model focuses on the proactive preservation of biological assets to address age-related and degenerative conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Korea Stem Cell Bank.